SARS-CoV-2 Vaccine-induced Humoral and Cellular Immunity in Patients with Hematologic Malignancies

Overview

Journal Semin Hematol

Specialty Hematology

Date 2023 Feb 22

PMID 36805887

Authors

Sabine Haggenburg

Quincy Hofsink

Caroline E Rutten

Inger S Nijhof

Mette D Hazenberg

Abraham Goorhuis

Affiliations

Soon will be listed here.

Abstract

Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3-dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses. The effect of 3-dose vaccination schedules and COVID-19 booster vaccinations on the protection of patients with hematologic malignancies against severe COVID-19 and COVID-19 related death remains to be confirmed by population-based vaccine effectiveness studies.

Citing Articles

Hepatitis a vaccine immunogenicity and boostability in adults receiving immunosuppressive therapy and adults living with HIV: a prospective single-centre cohort study.

Schnyder J, Garcia Garrido H, Tanck M, Maurer I, Harskamp A, Kootstra N J Travel Med. 2024; 32(2).

PMID: 39259891 PMC: 11896842. DOI: 10.1093/jtm/taae125.

Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party....

Spanjaart A, Ljungman P, Tridello G, Schwartz J, Martinez-Cibrian N, Barba P Leukemia. 2024; 38(9):1985-1991.

PMID: 39043963 PMC: 11347385. DOI: 10.1038/s41375-024-02336-1.

Increase in antibody titer and change over time associated with severe acute respiratory syndrome coronavirus 2 infection after mRNA vaccination: Consideration of the significance of additional vaccination.

Kusunoki H, Ohkusa M, Iida R, Saito A, Kawahara M, Ekawa K Clin Case Rep. 2024; 12(6):e8953.

PMID: 38808194 PMC: 11130231. DOI: 10.1002/ccr3.8953.

Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin's Lymphoma: A Single-Center Cohort Study.

Saito M, Mori A, Ishio T, Kobayashi M, Tsukamoto S, Kajikawa S Viruses. 2024; 16(3).

PMID: 38543695 PMC: 10974858. DOI: 10.3390/v16030328.

COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.

Kakavandi S, Hajikhani B, Azizi P, Aziziyan F, Nabi-Afjadi M, Farani M Cell Commun Signal. 2024; 22(1):126.

PMID: 38360719 PMC: 10868124. DOI: 10.1186/s12964-023-01316-9.

References

Feng S, Phillips D, White T, Sayal H, Aley P, Bibi S . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(11):2032-2040. PMC: 8604724. DOI: 10.1038/s41591-021-01540-1. View

Malard F, Gaugler B, Gozlan J, Bouquet L, Fofana D, Siblany L . Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer J. 2021; 11(8):142. PMC: 8353615. DOI: 10.1038/s41408-021-00534-z. View

Thompson M, Natarajan K, Irving S, Rowley E, Griggs E, Gaglani M . Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August.... MMWR Morb Mortal Wkly Rep. 2022; 71(4):139-145. PMC: 9351525. DOI: 10.15585/mmwr.mm7104e3. View

Den Hartog G, Schepp R, Kuijer M, GeurtsvanKessel C, van Beek J, Rots N . SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. J Infect Dis. 2020; 222(9):1452-1461. PMC: 7454740. DOI: 10.1093/infdis/jiaa479. View

GeurtsvanKessel C, Geers D, Schmitz K, Mykytyn A, Lamers M, Bogers S . Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Sci Immunol. 2022; 7(69):eabo2202. PMC: 8939771. DOI: 10.1126/sciimmunol.abo2202. View

Li C, Lee A, Grigoryan L, Arunachalam P, Scott M, Trisal M . Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat Immunol. 2022; 23(4):543-555. PMC: 8989677. DOI: 10.1038/s41590-022-01163-9. View

Knezevic I, Mattiuzzo G, Page M, Minor P, Griffiths E, Nuebling M . WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe. 2021; 3(3):e235-e240. PMC: 8547804. DOI: 10.1016/S2666-5247(21)00266-4. View

Bruxvoort K, Sy L, Qian L, Ackerson B, Luo Y, Lee G . Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study. Lancet Reg Health Am. 2021; 6:100134. PMC: 8614600. DOI: 10.1016/j.lana.2021.100134. View

Naranbhai V, Garcia-Beltran W, Chang C, Berrios Mairena C, Thierauf J, Kirkpatrick G . Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines. J Infect Dis. 2021; 225(7):1141-1150. PMC: 8689763. DOI: 10.1093/infdis/jiab593. View

10.

Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y . Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021; 137(23):3165-3173. PMC: 8061088. DOI: 10.1182/blood.2021011568. View

11.

Castano-Jaramillo L, Yamazaki-Nakashimada M, OFarrill-Romanillos P, Muzquiz Zermeno D, Scheffler Mendoza S, Venegas Montoya E . COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico. J Clin Immunol. 2021; 41(7):1463-1478. PMC: 8191444. DOI: 10.1007/s10875-021-01077-5. View

12.

Hippisley-Cox J, Coupland C, Mehta N, Keogh R, Diaz-Ordaz K, Khunti K . Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ. 2021; 374:n2244. PMC: 8446717. DOI: 10.1136/bmj.n2244. View

13.

How J, Gallagher K, Liu Y, Katsis K, Elder E, Larson R . Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients. Leukemia. 2022; 36(4):1176-1179. PMC: 8873343. DOI: 10.1038/s41375-022-01533-0. View

14.

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View

15.

Herzberg J, Fischer B, Becher H, Becker A, Honarpisheh H, Guraya S . Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study. Front Immunol. 2022; 13:896151. PMC: 9286388. DOI: 10.3389/fimmu.2022.896151. View

16.

Bange E, Han N, Wileyto P, Kim J, Gouma S, Robinson J . CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021; 27(7):1280-1289. PMC: 8291091. DOI: 10.1038/s41591-021-01386-7. View

17.

Oosting S, van der Veldt A, GeurtsvanKessel C, Fehrmann R, van Binnendijk R, Dingemans A . mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021; 22(12):1681-1691. PMC: 8577843. DOI: 10.1016/S1470-2045(21)00574-X. View

18.

Lee L, Ionescu M, Starkey T, Little M, Tilby M, Tripathy A . COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study. Eur J Cancer. 2022; 175:1-10. PMC: 9276646. DOI: 10.1016/j.ejca.2022.06.038. View

19.

Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Foca E . Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol. 2020; 31(5):565-569. PMC: 7264678. DOI: 10.1111/pai.13263. View

20.

Barda N, Dagan N, Cohen C, Hernan M, Lipsitch M, Kohane I . Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021; 398(10316):2093-2100. PMC: 8555967. DOI: 10.1016/S0140-6736(21)02249-2. View